AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00583128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: oral, sachet, 2 grams three times daily for 8 weeks
Study NCT00583128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celphere® CP-305
Description: oral, placebo, sachet, 2 grams three times daily for 8 weeks
Study NCT01278186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Description: Coronary angioplasty using the paclitaxel-coated balloon catheter
Study NCT01278186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Coronary angioplasty using the paclitaxel-eluting stent
Study NCT00830271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl plus and Monocryl plus
Description: closure of skin and subcutaneous tissues
Study NCT00830271 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wound closure with Vicryl and Monocryl
Description: wound closure skin and subcutaneous tissues
Study NCT03533608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group PE
Description: Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
Study NCT00865306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents.
Description: This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments.
Study NCT03941756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given IV
Study NCT03942757 — intervention group
Intervention type: OTHER
Intervention: bilirubin serum level determination
Description: bilirubin serum level before and after phototherapy treatment will be measured
Study NCT03942757 — intervention group
Intervention type: OTHER
Intervention: Phototherapy
Description: Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
Study NCT03941756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: Undergo lymphangiography
Study NCT03941756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous Bypass
Description: Undergo LVB
Study NCT01975701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Capsule for oral use.
Study NCT00435331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride (6R-BH4)
Description: 2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
Study NCT03439241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast ostomy device
Description: the test product is a newly developed Coloplast ostomy device
Study NCT02588898 — intervention group
Intervention type: DEVICE
Intervention: Blood collection and electrophysiological tests
Description: Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
Study NCT00776841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Study NCT01655498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal bowel control system (LivSure)
Study NCT04109209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention Group
Description: The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
Study NCT04109209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
Study NCT02167230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jailed-balloon technique
Description: A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
Study NCT02167230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jailed-wire technique
Description: A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
Study NCT01928888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid (Hydrotalcite, BAY4516H)
Description: 2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
Study NCT00776841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Study NCT00776841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg
Study NCT00776841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: Oral Aramchol at dose 30 mg to 900 mg
Study NCT01928888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
Study NCT01928888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
Study NCT00776841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Study NCT04223141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIA
Description: As indicated by arm description
Study NCT02246556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dichoptic therapy
Description: Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
Study NCT02246556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching therapy
Description: Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Study NCT02246556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dioptic (non-dichoptic) therapy
Description: Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Study NCT01686256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Description: Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
Study NCT00874172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid optimized analgesic strategy
Description: Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus
Study NCT00874172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: current analgesic strategy
Description: paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration
Study NCT04232410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Drug induced sleep endoscopy
Description: DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
Study NCT04232410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of critical closing pressure of the uppper airway
Description: After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
Study NCT04160871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
Study NCT04160871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation.
Study NCT00988429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 mg QD Eslicarbazepine acetate
Description: Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
Study NCT00988429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200 mg QD Eslicarbazepine acetate
Description: Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
Study NCT00988429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given QD
Study NCT02112799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVR 3-778
Study NCT02112799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NVR 3-778
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule
Study NCT02112799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Study NCT02112799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Study NCT05734235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Two Vitamin C tablets daily for 8 days.
Study NCT03920527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg
Description: Duration of itraconazole
Study NCT03920527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 400 mg
Description: Duration of itraconazole
Study NCT02729545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tung's acupuncture
Description: The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
Study NCT02729545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone acetate/ethinylestradiol (CPA/EE)
Description: Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
Study NCT00379925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Dietary Health Promotion Program
Description: Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 1
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 2
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 3
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 4
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 5
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 6
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Comparator 1
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Comparator 2
Study NCT00664417 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: 0.5 mL, IM, 2 injections
Study NCT02364414 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3Shape TRIOS (R)
Description: Direct intra-oral scan of teeth and dentition
Study NCT01929837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-fied navigated rTMS
Description: 1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
Study NCT01929837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-navigated rTMS
Description: 1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
Study NCT01929837 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham E-field navigated rTMS
Study NCT01929837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated rTMS
Description: 1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
Study NCT01186744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
Study NCT01186744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID
Study NCT01186744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
Study NCT01186744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID
Study NCT00776841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Study NCT03820128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early diet intervention
Description: Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
Study NCT01059838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sentence recognition
Description: testing the ability for sentence recognition in quiet and in noise.
Study NCT01577212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Individualized dose escalation
Description: Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
Study NCT00397462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calf muscle pump stimulation
Description: Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
Study NCT02107807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Investigational H5N1 vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart
Study NCT02107807 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Seasonal Influenza Vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart
Study NCT00604734 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReCap Total Hip Resurfacing System
Description: This is a hip resurfacing system.
Study NCT00686231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 15mg
Description: 15mg Nitroglycerin applied topically to one wrist
Study NCT00686231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 30mg
Description: 30mg Nitroglycerin applied topically to one wrist
Study NCT00686231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg
Description: 20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
Study NCT00686231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 40mg
Description: 40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
Study NCT00686231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical skin moisturizing cream with same appearance as active agent
Study NCT03787849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
Study NCT03787849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
Study NCT02127008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of epidural fat
Description: During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
Study NCT02127008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No resection of epidural fat
Description: During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.